Open AccessVirus-receptor interactions of SARS-CoV-2 spikereceptor-binding domain and human neuropilin-1 b1 domain
Author(s) -
Sultan F. Alnomasy
Publication year - 2021
Publication title -
al-mi’galaẗ al-sa'udiyaẗ lī-ulum al-ḥayaẗ
Language(s) - English
Resource type - Journals
ISSN - 1319-562X
DOI - 10.1016/j.sjbs.2021.03.074
Subject(s) - neuropilin 1 , coronavirus , receptor , virology , covid-19 , spike protein , viral entry , angiotensin converting enzyme 2 , virus , biology , medicine , disease , cancer research , genetics , infectious disease (medical specialty) , viral replication , vascular endothelial growth factor , vegf receptors
In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wahan, China and it causes disease which is known as COVID-19. This infection spreads everywhere in the world, and it leads to an enormous number of death among individuals. The mystery issue about SARS-CoV-2 that appears not to have functions of a hemagglutinin and neuraminidase like other coronaviruses. Angiotensin-converting enzyme 2 (ACE2) is the main surface receptor for entering SARS-CoV-2 into the host cell. This entry process is mediated by binding the SARS-CoV-2 spike receptor-binding domain (RBD) to ACE2. Recently, researchers discover a new receptor responsible for the SARS-CoV-2 entry which is neuropilin-1 (NRP1). So, this work provides afford a knowledge of how the initial interaction between SARS-CoV-2 spike RBD and NRP1 b1 domain may occur. Understanding this interaction would be very necessary for drug design against SARS-CoV-2.